Business
Ainos Celebrates First Listing Anniversary on Nasdaq
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO, CA /
About this update from Ainos, Inc.
[{"type":"text","content":"Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (\"Ainos\", or the \"Company\"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is celebrating the one-year anniversary of its listing on the Nasdaq. To commemorate this important milestone, Nasdaq displayed a special congratulatory message on its MarketSite Tower in New York's Times Square. Image courtesy of Nasdaq, Inc.Chun-Hsien (Eddy) Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, \"We are delighted to celebrate our first listing anniversary on the Nasdaq and reflect on the progress we have achieved over the past year. Since our listing, we have achieved several significant milestones that demonstrate our commitment to diversifying and growing our revenues and to building a capital efficient business model.\"\"First, we successfully commercialized Ainos COVID-19 test kits in Taiwan, providing a crucial tool in the fight against the pandemic during 2022. In June 2023, we launched five VELDONA® Pet cytoprotein health supplements in Taiwan, with the target of expanding into new markets and achieving revenues of approximately US$20 million in 2024. We have also established multiple strategic relationships, including one with Swiss Pharmaceutical for VELDONA® human drug manufacturing and another with Topmed International Biotech for marketing VELDONA® Pet in Taiwan. Our fundraising efforts have proven fruitful, with a $3 million private placement in March that we believe will help us accelerate our growth and innovation.\" \"Looking ahead to the remainder of 2023, we are thrilled to be embarking on a new growth phase. We have partnered with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to co-develop a volatile organic compound sensing platform for applications including telehealth, automotive, industrial, and environmental safety. We believe we have formed a strong team to drive our vision of digitizing smell and creating potential hardware and licensing revenues for Ainos. We are also excited for the business pote...